Synteract, Inc. (San Diego) Releases SynCapture Version 1.5 of Its Hybrid Electronic Data Capture (EDC) System
Published: Feb 01, 2012
SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- Synteract, Inc., a full-service contract research organization (CRO), has released upgrades to its electronic data capture system SynCapture, providing customers with increased user functionality. SynCapture allows for clinical study data to be captured into a single database using multiple modes of entry including paper, fax, and web based, resulting in more seamless, flexible and cost effective data capture.
"We understand that low cost EDC is critical, especially in smaller trials," said Wendel Barr, chief executive officer at Synteract. "SynCapture has been an effective solution to handle the needs of our clients since it was first implemented in 2005. SynCapture 1.5 integrates features that enhance our cost efficient EDC offering, so we can continue to meet each client's unique program requirements."
SynCapture 1.5 provides users the ability to re-query investigative sites on data collected, an upgrade sponsors requested. In addition, the new release brings enhanced audit trail legibility and functionality useful to all project team members, as well as features that increase the ease and efficiency of the query resolution process.
"SynCapture 1.5 provides users increased functionality and easier data collection," said Olivia Montano, senior director of clinical data management at Synteract. "The main reason for the upgrade was to improve the user experience. We took into account direct requests from users, since customer service is so integral to what we do at Synteract. This SynCapture upgrade allows us to provide clients an improved option for on-time delivery of quality data to help them get to decision points faster."
About Synteract, Inc.
Synteract is a privately-held, full-service contract research organization, serving clinical trial needs of biotechnology, medical device, and pharmaceutical companies. Synteract provides high quality, customized service, working closely with drug and device sponsors. Headquartered in California, with offices in North Carolina and Czech Republic, Synteract offers clinical expertise in multiple therapeutic areas, including a strong emphasis in oncology, central nervous system (CNS), cardiovascular, respiratory, and ophthalmology. Information: http://www.synteract.com; (760) 268.8200.
Clearpoint Agency, for Synteract
SOURCE Synteract, Inc.